{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:03:37Z","timestamp":1794661417544,"version":"4.9.1"},"reference-count":88,"publisher":"American Society of Hematology","issue":"15","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/legalcode"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hairy cell leukemia (HCL) responds very well to frontline chemotherapy with purine analogs (cladribine and pentostatine). However, approximately half of patients experience 1 or more relapses, which become progressively resistant to these myelotoxic and immunosuppressive agents. At progression, standard therapeutic options include a second course of purine analogs alone or in combination with rituximab and, upon second relapse, therapy with the anti-CD22 immunotoxin moxetumomab pasudotox. Furthermore, blockade of the mutant BRAF-V600E kinase (the pathogenetic hallmark of HCL) through orally available specific inhibitors (vemurafenib or dabrafenib) effaces the peculiar morphologic, phenotypic, and molecular identity of this disease and its typical antiapoptotic behavior and is emerging as an attractive chemotherapy-free strategy in various clinical scenarios. These include patients with, or at risk of, severe infections and, in a highly effective combination with rituximab, patients with relapsed or refractory HCL. Other treatments explored in clinical trials are BTK inhibition with ibrutinib and co-inhibition of BRAF (through dabrafenib or vemurafenib) and its downstream target MEK (through trametinib or cobimetinib). Here, we focus on our experience with BRAF inhibitors in clinical trials and as off-label use in routine practice by presenting 3 challenging clinical cases to illustrate their management in the context of all available treatment options.<\/jats:p>","DOI":"10.1182\/blood.2021013502","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T13:59:06Z","timestamp":1644501546000},"page":"2294-2305","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["How I treat refractory\/relapsed hairy cell leukemia with BRAF inhibitors"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7198-5965","authenticated-orcid":false,"given":"Brunangelo","family":"Falini","sequence":"first","affiliation":[{"name":"Section of Hematology and Center for Hemato-Oncological Research (CREO), Department of Medicine and Surgery, University of Perugia and Hospital Santa Maria della Misericordia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"De Carolis","sequence":"additional","affiliation":[{"name":"Section of Hematology and Center for Hemato-Oncological Research (CREO), Department of Medicine and Surgery, University of Perugia and Hospital Santa Maria della Misericordia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Tiacci","sequence":"additional","affiliation":[{"name":"Section of Hematology and Center for Hemato-Oncological Research (CREO), Department of Medicine and Surgery, University of Perugia and Hospital Santa Maria della Misericordia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2022041415222872800_B1","first-page":"226","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Foucar","year":"2017"},{"issue":"1","key":"2022041415222872800_B2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2009-06-195370","article-title":"How I treat hairy cell leukemia","volume":"115","author":"Grever","year":"2010","journal-title":"Blood."},{"issue":"9424","key":"2022041415222872800_B3","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(04)16356-3","article-title":"Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1)","volume":"363","author":"Falini","year":"2004","journal-title":"Lancet."},{"issue":"1","key":"2022041415222872800_B4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.20031175","article-title":"Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors","volume":"199","author":"Basso","year":"2004","journal-title":"J Exp Med."},{"issue":"6","key":"2022041415222872800_B5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrc1888","article-title":"Evolving concepts in the pathogenesis of hairy-cell leukaemia","volume":"6","author":"Tiacci","year":"2006","journal-title":"Nat Rev Cancer."},{"issue":"12","key":"2022041415222872800_B6","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1038\/leu.2012.149","article-title":"A microRNA signature specific for hairy cell leukemia and associated with modulation of the MAPK-JNK pathways","volume":"26","author":"Kitagawa","year":"2012","journal-title":"Leukemia."},{"issue":"24","key":"2022041415222872800_B7","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med."},{"issue":"5","key":"2022041415222872800_B8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood."},{"issue":"2","key":"2022041415222872800_B9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2013-06-508754","article-title":"Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series","volume":"123","author":"Rosenberg","year":"2014","journal-title":"Blood."},{"issue":"4","key":"2022041415222872800_B10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.beha.2015.09.004","article-title":"Long-term follow-up after purine analogue therapy in hairy cell leukaemia","volume":"28","author":"Else","year":"2015","journal-title":"Best Pract Res Clin Haematol."},{"issue":"1","key":"2022041415222872800_B11","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/asheducation.V2012.1.660.3798659","article-title":"Immunoconjugates and new molecular targets in hairy cell leukemia","volume":"2012","author":"Kreitman","year":"2012","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"issue":"1","key":"2022041415222872800_B12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bjh.17440","article-title":"The current role of interferon in hairy cell leukaemia: clinical and molecular aspects","volume":"194","author":"Assanto","year":"2021","journal-title":"Br J Haematol."},{"issue":"1","key":"2022041415222872800_B13","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1634\/theoncologist.2019-0370","article-title":"Contextualizing the use of moxetumomab pasudotox in the treatment of relapsed or refractory hairy cell leukemia","volume":"25","author":"Kreitman","year":"2020","journal-title":"Oncologist."},{"issue":"1","key":"2022041415222872800_B14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-020-01004-y","article-title":"Moxetumomab pasudotox in heavily pre-treated patients with relapsed\/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial","volume":"14","author":"Kreitman","year":"2021","journal-title":"J Hematol Oncol."},{"issue":"15","key":"2022041415222872800_B15","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood-2016-07-418434","article-title":"BRAF V600E mutation in hairy cell leukemia: from bench to bedside","volume":"128","author":"Falini","year":"2016","journal-title":"Blood."},{"issue":"9","key":"2022041415222872800_B16","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/JCO.2016.71.1556","article-title":"Genomics of hairy cell leukemia","volume":"35","author":"Tiacci","year":"2017","journal-title":"J Clin Oncol."},{"key":"2022041415222872800_B17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/hon.2594","article-title":"New treatment options in hairy cell leukemia with focus on BRAF inhibitors","volume":"37","author":"Falini","year":"2019","journal-title":"Hematol Oncol."},{"issue":"8","key":"2022041415222872800_B18","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3390\/biom10081140","article-title":"Development of recombinant immunotoxins for hairy cell leukemia","volume":"10","author":"Kreitman","year":"2020","journal-title":"Biomolecules."},{"issue":"8","key":"2022041415222872800_B19","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia."},{"issue":"19","key":"2022041415222872800_B20","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1182\/bloodadvances.2019000507","article-title":"Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval","volume":"3","author":"Lin","year":"2019","journal-title":"Blood Adv."},{"issue":"4","key":"2022041415222872800_B21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3324\/haematol.2012.078071","article-title":"Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia","volume":"98","author":"Tiacci","year":"2013","journal-title":"Haematologica."},{"issue":"8","key":"2022041415222872800_B22","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2014-10-603100","article-title":"BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity","volume":"125","author":"Pettirossi","year":"2015","journal-title":"Blood."},{"issue":"21","key":"2022041415222872800_B23","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMc1202124","article-title":"BRAF inhibition in refractory hairy-cell leukemia","volume":"366","author":"Dietrich","year":"2012","journal-title":"N Engl J Med."},{"issue":"1","key":"2022041415222872800_B24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/bjh.12201","article-title":"Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib","volume":"161","author":"Follows","year":"2013","journal-title":"Br J Haematol."},{"issue":"2","key":"2022041415222872800_B25","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3324\/haematol.2012.082404","article-title":"Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation","volume":"98","author":"Peyrade","year":"2013","journal-title":"Haematologica."},{"issue":"20","key":"2022041415222872800_B26","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1200\/JCO.2012.45.7739","article-title":"Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation","volume":"31","author":"Munoz","year":"2013","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022041415222872800_B27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1056\/NEJMc1310849","article-title":"Efficacy of vemurafenib in hairy-cell leukemia","volume":"370","author":"Samuel","year":"2014","journal-title":"N Engl J Med."},{"issue":"1","key":"2022041415222872800_B28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.18632\/oncoscience.111","article-title":"Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib","volume":"2","author":"Bailleux","year":"2014","journal-title":"Oncoscience."},{"issue":"12","key":"2022041415222872800_B29","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00277-014-2104-2","article-title":"Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib","volume":"93","author":"Vergote","year":"2014","journal-title":"Ann Hematol."},{"issue":"1","key":"2022041415222872800_B30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.6004\/jnccn.2015.0004","article-title":"Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib","volume":"13","author":"Blachly","year":"2015","journal-title":"J Natl Compr Canc Netw."},{"issue":"23","key":"2022041415222872800_B31","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2015-11-680074","article-title":"BRAF inhibition in hairy cell leukemia with low-dose vemurafenib","volume":"127","author":"Dietrich","year":"2016","journal-title":"Blood."},{"issue":"5","key":"2022041415222872800_B32","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/s41375-019-0646-y","article-title":"BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials","volume":"34","author":"Liebers","year":"2020","journal-title":"Leukemia."},{"issue":"18","key":"2022041415222872800_B33","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N Engl J Med."},{"issue":"11","key":"2022041415222872800_B34","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/s41375-021-01210-8","article-title":"Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial","volume":"35","author":"Tiacci","year":"2021","journal-title":"Leukemia."},{"issue":"19","key":"2022041415222872800_B35","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2031298","article-title":"Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia","volume":"384","author":"Tiacci","year":"2021","journal-title":"N Engl J Med."},{"issue":"9","key":"2022041415222872800_B36","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med."},{"issue":"26","key":"2022041415222872800_B37","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med."},{"issue":"8","key":"2022041415222872800_B38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med."},{"issue":"13","key":"2022041415222872800_B39","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.3390\/jcm10132800","article-title":"Vemurafenib and rituximab in patients with hairy cell leukemia previously treated with moxetumomab pasudotox","volume":"10","author":"Robak","year":"2021","journal-title":"J Clin Med."},{"issue":"1","key":"2022041415222872800_B40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood-2011-08-371179","article-title":"Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation","volume":"119","author":"Tiacci","year":"2012","journal-title":"Blood."},{"issue":"1","key":"2022041415222872800_B41","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2011-08-368209","article-title":"The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms","volume":"119","author":"Arcaini","year":"2012","journal-title":"Blood."},{"issue":"13","key":"2022041415222872800_B42","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1182\/blood-2011-10-383323","article-title":"Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia","volume":"119","author":"Schnittger","year":"2012","journal-title":"Blood."},{"issue":"5","key":"2022041415222872800_B43","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2141.2011.08868.x","article-title":"High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies","volume":"155","author":"Boyd","year":"2011","journal-title":"Br J Haematol."},{"issue":"12","key":"2022041415222872800_B44","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1097\/PAS.0b013e3182549b50","article-title":"Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia","volume":"36","author":"Andrulis","year":"2012","journal-title":"Am J Surg Pathol."},{"issue":"1","key":"2022041415222872800_B45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1309\/AJCPQLQ89VXTVWKN","article-title":"The utility of BRAF V600E mutation-specific antibody VE1 for the diagnosis of hairy cell leukemia","volume":"143","author":"Uppal","year":"2015","journal-title":"Am J Clin Pathol."},{"issue":"1","key":"2022041415222872800_B46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1309\/AJCPDN4Q1JTFGCFC","article-title":"Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia","volume":"143","author":"Brown","year":"2015","journal-title":"Am J Clin Pathol."},{"issue":"4","key":"2022041415222872800_B47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.beha.2015.10.020","article-title":"Hairy cell leukemia: uncommon clinical features, unusual sites of involvement and some rare associations","volume":"28","author":"Tadmor","year":"2015","journal-title":"Best Pract Res Clin Haematol."},{"issue":"3","key":"2022041415222872800_B48","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2141.2010.08359.x","article-title":"Hairy cell leukaemia, negative for conventional cell markers, diagnosed using antibodies to annexin A1 and T-bet","volume":"151","author":"Sadik","year":"2010","journal-title":"Br J Haematol."},{"issue":"4","key":"2022041415222872800_B49","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.beha.2015.10.019","article-title":"Bone marrow and splenic histology in hairy cell leukaemia","volume":"28","author":"Wotherspoon","year":"2015","journal-title":"Best Pract Res Clin Haematol."},{"issue":"1","key":"2022041415222872800_B50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12253-014-9807-5","article-title":"A comprehensive immunophenotypic marker analysis of hairy cell leukemia in paraffin-embedded bone marrow trephine biopsies\u2013a tissue microarray study","volume":"21","author":"T\u00f3th-Lipt\u00e1k","year":"2015","journal-title":"Pathol Oncol Res."},{"issue":"22","key":"2022041415222872800_B51","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1158\/1078-0432.CCR-13-1848","article-title":"Bendamustine and rituximab in relapsed and refractory hairy cell leukemia","volume":"19","author":"Burotto","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"7","key":"2022041415222872800_B52","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/bcp.14250","article-title":"Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia","volume":"86","author":"Kuruvilla","year":"2020","journal-title":"Br J Clin Pharmacol."},{"issue":"9","key":"2022041415222872800_B53","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer."},{"issue":"3","key":"2022041415222872800_B54","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med."},{"issue":"23","key":"2022041415222872800_B55","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1158\/1078-0432.CCR-15-0469","article-title":"Multiple gastrointestinal polyps in patients treated with BRAF inhibitors","volume":"21","author":"Amaravadi","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"24","key":"2022041415222872800_B56","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1056\/NEJMoa1208958","article-title":"Progression of RAS-mutant leukemia during RAF inhibitor treatment","volume":"367","author":"Callahan","year":"2012","journal-title":"N Engl J Med."},{"issue":"4","key":"2022041415222872800_B57","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/bjh.12964","article-title":"The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7\/del(7q)","volume":"166","author":"McNerney","year":"2014","journal-title":"Br J Haematol."},{"issue":"14","key":"2022041415222872800_B58","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/bloodadvances.2018028423","article-title":"Distinct clinical and biological implications of CUX1 in myeloid neoplasms","volume":"3","author":"Aly","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"2022041415222872800_B59","doi-asserted-by":"crossref","first-page":"18622","DOI":"10.1038\/s41598-020-74744-z","article-title":"Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome","volume":"10","author":"Wang","year":"2020","journal-title":"Sci Rep."},{"issue":"539","key":"2022041415222872800_B60","doi-asserted-by":"crossref","first-page":"eaao5617","DOI":"10.1126\/scisignal.aao5617","article-title":"Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia","volume":"11","author":"Jenkins","year":"2018","journal-title":"Sci Signal."},{"issue":"3","key":"2022041415222872800_B61","doi-asserted-by":"crossref","DOI":"10.1177\/0300060519891013","article-title":"Prognostic significance of U2AF1 mutations in myelodysplastic syndromes: a meta-analysis","volume":"48","author":"Li","year":"2020","journal-title":"J Intern Med Res."},{"issue":"3-4","key":"2022041415222872800_B62","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/10428199409056295","article-title":"Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL)","volume":"13","author":"Frassoldati","year":"1994","journal-title":"Leuk Lymphoma."},{"issue":"10","key":"2022041415222872800_B63","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood.V83.10.2906.2906","article-title":"2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia","volume":"83","author":"Seymour","year":"1994","journal-title":"Blood."},{"issue":"1","key":"2022041415222872800_B64","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.leu.2400513","article-title":"Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up","volume":"11","author":"Seymour","year":"1997","journal-title":"Leukemia."},{"issue":"3","key":"2022041415222872800_B65","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/jinf.2001.0816","article-title":"Remember mycobacterial disease in hairy cell leukaemia (HCL)","volume":"42","author":"Thaker","year":"2001","journal-title":"J Infect."},{"issue":"1","key":"2022041415222872800_B66","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1056\/NEJMcps1404270","article-title":"Clinical problem-solving. A man with fever, cough, and rash","volume":"373","author":"Geller","year":"2015","journal-title":"N Engl J Med."},{"key":"2022041415222872800_B67","first-page":"5616898","article-title":"Listeria monocytogenes infection in hairy cell leukemia: a case report and literature review","volume":"2018","author":"Barton","year":"2018","journal-title":"Case Rep Hematol."},{"key":"2022041415222872800_B68","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/10428194.2011.570819","article-title":"Infectious complications in hairy cell leukemia","volume":"52","author":"Kraut","year":"2011","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2022041415222872800_B69","doi-asserted-by":"crossref","first-page":"e28574","DOI":"10.1002\/pbc.28574","article-title":"Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction","volume":"68","author":"Shah","year":"2021","journal-title":"Pediatr Blood Cancer."},{"issue":"2","key":"2022041415222872800_B70","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/bloodadvances.2018027466","article-title":"Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib","volume":"3","author":"Shenoi","year":"2019","journal-title":"Blood Adv."},{"issue":"6","key":"2022041415222872800_B71","doi-asserted-by":"crossref","first-page":"E180","DOI":"10.1002\/ajh.25474","article-title":"Low-dose vemurafenib in hairy cell leukemia patients with active infection","volume":"94","author":"Bohn","year":"2019","journal-title":"Am J Hematol."},{"key":"2022041415222872800_B72","doi-asserted-by":"crossref","first-page":"106315","DOI":"10.1016\/j.leukres.2020.106315","article-title":"Disseminated, yet dissembled: rare infections behind the veil of classical hairy cell leukemia","volume":"90","author":"Shallis","year":"2020","journal-title":"Leuk Res."},{"issue":"7","key":"2022041415222872800_B73","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clml.2021.02.005","article-title":"Inhibitor of BRAFV600E mutation as a treatment option for hairy cell leukemia with deep neutropenia and infectious complications","volume":"21","author":"Smirnova","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"25","key":"2022041415222872800_B74","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1182\/blood.2020009688","article-title":"Phase 2 study of ibrutinib in classic and variant hairy cell leukemia","volume":"137","author":"Rogers","year":"2021","journal-title":"Blood."},{"issue":"9992","key":"2022041415222872800_B75","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet."},{"issue":"1","key":"2022041415222872800_B76","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov."},{"issue":"22","key":"2022041415222872800_B77","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1182\/blood-2011-12-400374","article-title":"Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia","volume":"119","author":"Tiacci","year":"2012","journal-title":"Blood."},{"issue":"1","key":"2022041415222872800_B78","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2012.163","article-title":"Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins","volume":"27","author":"Weston-Bell","year":"2013","journal-title":"Leukemia."},{"issue":"2","key":"2022041415222872800_B79","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41375-018-0270-2","article-title":"Targeting MEK in vemurafenib-resistant hairy cell leukemia","volume":"33","author":"Caeser","year":"2019","journal-title":"Leukemia."},{"issue":"6","key":"2022041415222872800_B80","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and immune evolution of melanoma acquiring MAPKi resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell."},{"key":"2022041415222872800_B81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2016.12.012","article-title":"MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur J Cancer."},{"key":"2022041415222872800_B82","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2018-99-113135","article-title":"Treatment with combination of dabrafenib and trametinib in patients with recurrent\/refractory BRAF V600E-mutated hairy cell leukemia (HCL)","volume":"32","author":"Kreitman","year":"2018","journal-title":"Blood."},{"issue":"7","key":"2022041415222872800_B83","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1038\/s41375-021-01257-7","article-title":"Hairy cell leukemia and COVID-19 adaptation of treatment guidelines","volume":"35","author":"Grever","year":"2021","journal-title":"Leukemia."},{"issue":"7830","key":"2022041415222872800_B84","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses [published correction appears in Nature. 2021;590(7844):E17]","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature."},{"issue":"7","key":"2022041415222872800_B85","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med."},{"issue":"23","key":"2022041415222872800_B86","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood."},{"key":"2022041415222872800_B87","doi-asserted-by":"crossref","first-page":"598319","DOI":"10.3389\/fonc.2021.598319","article-title":"In vitro sensitivity and microenvironment protection in hairy cell leukemia","volume":"11","author":"Vereertbrugghen","year":"2021","journal-title":"Front Oncol."},{"key":"2022041415222872800_B88","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2018-99-113135","article-title":"Treatment with combination of dabrafenib and trametinib in patients with recurrent\/refractory BRAF V600E-mutated hairy cell leukemia (HCL)","volume":"132","author":"Kreitman","year":"2018","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/15\/2294\/1891111\/bloodbld2021013502.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/15\/2294\/1891111\/bloodbld2021013502.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:24:15Z","timestamp":1649935455000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/15\/2294\/483952\/How-I-treat-refractory-relapsed-hairy-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":88,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021013502","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]}}}